Enfuvirtide antiretroviral therapy in HIV-1 infection

Christina M.R. Kitchen, Miriam A Nuno, Scott G. Kitchen, Paul Krogstad

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number2
StatePublished - May 28 2008
Externally publishedYes

Keywords

  • Drug resistance
  • Enfuvirtide
  • Evolution
  • gp41
  • HIV
  • Salvage therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Chemical Health and Safety
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Enfuvirtide antiretroviral therapy in HIV-1 infection'. Together they form a unique fingerprint.

  • Cite this

    Kitchen, C. M. R., Nuno, M. A., Kitchen, S. G., & Krogstad, P. (2008). Enfuvirtide antiretroviral therapy in HIV-1 infection. Therapeutics and Clinical Risk Management, 4(2), 433-439.